Fadini, G. P. http://orcid.org/0000-0002-6510-2097
Boscari, F.
Falaguasta, D.
Ferretto, S.
Maran, A.
Avogaro, A.
Bruttomesso, D.
Article History
Received: 25 November 2021
Accepted: 13 January 2022
First Online: 1 February 2022
Declarations
:
: GPF received grants, consultancy or lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novo Nordisk, Novartis, Sanofi, Servier, Takeda. FB have received lecture fees from Abbott and Roche, Eli Lilly, Lifescan, Sanofi. AA received research grants, lecture or advisory board fees from: Merck-Sharp-Dome, AstraZeneca, Novartis, Boehringer-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, Takeda. DB have received lecture fees from Abbott, Lilly, Roche, Sanofi and advisory board fees from AstraZeneca, Becton Dickinson, Sanofi. DF, SF, and AM have nothing to disclose. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. GPF is an Associate Editor for the Journal of Endocrinological Investigations.
: The study was conducted in agreement with the principles of the declaration of Helsinki. The protocol was cleared to by the Ethical Committee of the University Hospital of Padova (prot. no. 177n/AO/21).
: Patients provided written informed consent.